Lescarden Receives Patent for Osteoarthritis Treatment
May 6, 2002
1 Min Read
Lescarden Receives Patent for Osteoarthritis Treatment
NEW YORK--Lescarden Inc. (www.lescarden.com) was awarded a U.S. patent (No. 6,117,851) for its product, Poly-NAG®, as a treatment forosteoarthritis. The patent filing included clinical trials on the bioavailability and product efficacy in patients suffering fromosteoarthritis. Poly-NAG (poly-N-acetyl-D-glucosamine) is derived from shellfish chitin and is a specially processed short chain polymer ofglucosamine.
Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
You May Also Like